Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Diurnal Group Plc - news published 25 - readings 1.225

BACK

Diurnal Group plc

Notification of major holdings

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 01 November 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 01 November 2022 09:12:09 UTC .

01.11.2022

Diurnal Group plc

EXERCISE OF OPTIONS

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 28 October 2022 16:07:31 UTC .

28.10.2022

Diurnal Group plc

RESULTS OF COURT MEETING AND GENERAL MEETING

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 21 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 21 October 2022 12:44:18 UTC .

21.10.2022

Diurnal Group plc

Standard form for notification of major holdings

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 12 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 12 October 2022 11:41:14 UTC .

12.10.2022

Diurnal Group plc

Block Admission Application

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 11 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 11 October 2022 06:10:25 UTC .

11.10.2022

Diurnal Group plc

AWMSG recommends Efmody for CAH in Wales

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 07 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 07 October 2022 06:07:18 UTC .

07.10.2022

Diurnal Group plc

AWMSG recommends Efmody® as treatment option for adolescents and adults with congenital adrenal hyperplasia in Wales

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the All Wales Medicines Strategy Group (AWMSG) has recommended Efmody ® (hydrocortisone modified-release hard capsules) as an option for restricted use to treat adolescents and adults with congenital adrenal hyperplasia (CAH) with ...

07.10.2022

Diurnal Group plc

Interim Results for the Twelve Months Ended 30 June 2022

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces its results for the twelve months ended 30 June 2022 (the "Period") and following the publication of a trading update on 26 July 2022. Operational highlights (including post-period): ● Proposed acquisition by Neurocrine Bios ...

14.09.2022

Diurnal Group plc

Standard form for notification of major holdings

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 07 September 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 07 September 2022 13:25:01 UTC .

07.09.2022

Diurnal Group plc

Trading Update

Revenues in line with current expectations; strong sales growth (+104%) driven by good Alkindi® performance and initial sales of Efmody® Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today provides an unaudited trading update for the twelve-month period ended 30 June 2022 (the "Period ...

26.07.2022

Diurnal Group plc

Distribution agreement signed with Vector Pharma for Alkindi®

Exclusive partnership covers 14 countries across the Middle East and North Africa Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces a distribution agreement with Vector Pharma FCZO ("Vector Pharma"), a leading full-service distributor, for the distribution of Alkindi® (hydro ...

30.03.2022

Diurnal Group plc

Interim Results for the Six Months Ended 31 December 2021

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces its results for the six months ended 31 December 2021 (the "Period") and follows the publication of a trading update on 26 January 2022. Operational highlights Commercial products o Alkindi® (hydrocortisone granules in capsul ...

22.03.2022

Diurnal Group plc

Trading update

Strong sales growth (+75%) driven by good Alkindi® performance and first sales of Efmody® Initial launches of Efmody® in Germany, UK and Austria in line with the Company's expectations Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today provides an unaudited trading update for the six mon ...

26.01.2022

Diurnal Group plc

Operational update - Jan 2022

First clinical trial sites initiated in both CONnECT and CHAMPAIN studies for Chronocort® DITEST™ IND application to be submitted during January 2022 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, provides an operational update on its ongoing clinical trial activity. Operational updates CH ...

11.01.2022

Diurnal Group plc

Results of AGM

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Diurnal Group plc published this content on 19 November 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 19 November 2021 12:08:09 UTC .

19.11.2021

Diurnal Group Plc - news published 25 - readings 1.225

Diurnal Group plc

Notification of major holdings

Diurnal Group plc

EXERCISE OF OPTIONS

Diurnal Group plc

RESULTS OF COURT MEETING AND GENERAL MEETING

Diurnal Group plc

Standard form for notification of major holdings

Diurnal Group plc

Block Admission Application

Diurnal Group plc

AWMSG recommends Efmody for CAH in Wales

Diurnal Group plc

AWMSG recommends Efmody® as treatment option for adolescents and adults with congenital adrenal hyperplasia in Wales

Diurnal Group plc

Interim Results for the Twelve Months Ended 30 June 2022

Diurnal Group plc

Standard form for notification of major holdings

Diurnal Group plc

Trading Update

Diurnal Group plc

Distribution agreement signed with Vector Pharma for Alkindi®

Diurnal Group plc

Interim Results for the Six Months Ended 31 December 2021

Diurnal Group plc

Trading update

Diurnal Group plc

Operational update - Jan 2022

Diurnal Group plc

Results of AGM

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member